Celltrion, Inc. And Medidata Team Up To Transform Global Clinical Trials For Biosimilars

NEW YORK & SEOUL, Korea--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and Korean biopharmaceutical company Celltrion (KOSDAQ:068270) today announced that the Seoul-based organization has adopted Medidata's industry-leading technology platform. A global leader in biosimilars R&D, Celltrion will rely on the Medidata Clinical Cloud® to enhance the speed, efficiency and accuracy of its clinical trials.

Back to news